Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joshua Brody

Showing results (21-30 of 44) with videos related to

Pageof 5
Sort By:
Journal of Translational Medicine|April 8, 2021
The "Great Debate" at Immunotherapy Bridge 2020, December 3rd, 2020Paolo A Ascierto, Joshua Brody, Lisa H Butterfield, et al.
Blood Advances|May 8, 2020
Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, for hematologic malignanciesStephen M Ansell, Ian Flinn, Matthew H Taylor, et al.
European Journal of Cancer (Oxford, England : 1990)|September 25, 2021
Current strategies for intratumoural immunotherapy - Beyond immune checkpoint inhibitionJianda Yuan, Anuradha Khilnani, Joshua Brody, et al.
Blood|April 5, 2018
SOX11 augments BCR signaling to drive MCL-like tumor developmentPei-Yu Kuo, Shashidhar S Jatiani, Adeeb H Rahman, et al.
Blood|April 27, 2016
A thrombopoietin receptor antagonist is capable of depleting myelofibrosis hematopoietic stem and progenitor cellsXiaoli Wang, David Haylock, Cing Siang Hu, et al.
Journal for Immunotherapy of Cancer|December 28, 2020
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphomaSattva S Neelapu, Sherry Adkins, Stephen M Ansell, et al.
Blood|January 9, 2013
High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cellsJune H Myklebust, Jonathan M Irish, Joshua Brody, et al.
Plos Genetics|August 23, 2013
β-Catenin-independent activation of TCF1/LEF1 in human hematopoietic tumor cells through interaction with ATF2 transcription factorsLuca Grumolato, Guizhong Liu, Tomomi Haremaki, et al.
Cancer Research|February 14, 2016
Dual Targeting of CDK4 and ARK5 Using a Novel Kinase Inhibitor ON123300 Exerts Potent Anticancer Activity against Multiple MyelomaDeepak Perumal, Pei-Yu Kuo, Violetta V Leshchenko, et al.
Blood|December 25, 2016
Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profilingJune H Myklebust, Joshua Brody, Holbrook E Kohrt, et al.
Pageof 5

Showing results (21-30 of 44) with videos related to

Sort By:
Pageof 5
Journal of Translational Medicine|April 8, 2021
The "Great Debate" at Immunotherapy Bridge 2020, December 3rd, 2020Paolo A Ascierto, Joshua Brody, Lisa H Butterfield, et al.
Blood Advances|May 8, 2020
Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, for hematologic malignanciesStephen M Ansell, Ian Flinn, Matthew H Taylor, et al.
European Journal of Cancer (Oxford, England : 1990)|September 25, 2021
Current strategies for intratumoural immunotherapy - Beyond immune checkpoint inhibitionJianda Yuan, Anuradha Khilnani, Joshua Brody, et al.
Blood|April 5, 2018
SOX11 augments BCR signaling to drive MCL-like tumor developmentPei-Yu Kuo, Shashidhar S Jatiani, Adeeb H Rahman, et al.
Blood|April 27, 2016
A thrombopoietin receptor antagonist is capable of depleting myelofibrosis hematopoietic stem and progenitor cellsXiaoli Wang, David Haylock, Cing Siang Hu, et al.
Journal for Immunotherapy of Cancer|December 28, 2020
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphomaSattva S Neelapu, Sherry Adkins, Stephen M Ansell, et al.
Blood|January 9, 2013
High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cellsJune H Myklebust, Jonathan M Irish, Joshua Brody, et al.
Plos Genetics|August 23, 2013
β-Catenin-independent activation of TCF1/LEF1 in human hematopoietic tumor cells through interaction with ATF2 transcription factorsLuca Grumolato, Guizhong Liu, Tomomi Haremaki, et al.
Cancer Research|February 14, 2016
Dual Targeting of CDK4 and ARK5 Using a Novel Kinase Inhibitor ON123300 Exerts Potent Anticancer Activity against Multiple MyelomaDeepak Perumal, Pei-Yu Kuo, Violetta V Leshchenko, et al.
Blood|December 25, 2016
Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profilingJune H Myklebust, Joshua Brody, Holbrook E Kohrt, et al.
Pageof 5